Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis

Hypertension Research

Volumn 30, Issue 7, 2007, Pages 621-626

  Ishimitsu, Toshihiko ^a   Kameda, Tomoko ^a   Akashiba, Akira ^a   Takahashi, Toshiaki ^a   Ohta, Satoshi ^a   Yoshii, Masayoshi ^a   Minami, Junichi ^a   Ono, Hidehiko ^a   Numabe, Atsushi ^a   Matsuoka, Hiroaki ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Aldosterone; Calcium channel blocker; Chronic glomerulonephritis; Efonidipine; Proteinuria

Indexed keywords

ALBUMIN; ALDOSTERONE; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EFONIDIPINE; IMMUNOSUPPRESSIVE AGENT; STEROID;

ALBUMIN BLOOD LEVEL; ALDOSTERONE BLOOD LEVEL; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BLOOD SAMPLING; CHRONIC GLOMERULONEPHRITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSSOVER PROCEDURE; DRUG DOSE TITRATION; DRUG MECHANISM; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MALE; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; URINALYSIS; URINARY EXCRETION;

ADULT; AGED; ALDOSTERONE; AMLODIPINE; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; CALCIUM CHANNELS, T-TYPE; CHRONIC DISEASE; CROSS-OVER STUDIES; DIHYDROPYRIDINES; FEMALE; GLOMERULONEPHRITIS; HUMANS; MALE; MIDDLE AGED; NITROPHENOLS; ORGANOPHOSPHORUS COMPOUNDS; PROTEINURIA;

EID: 34548028268     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.30.621     Document Type: Article

References (30)

1. Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM: Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol 1981; 241: F85-F93.
2. Brenner BM, Lawler EV, Mackenzie HS: The hyperfiltration theory: a paradigm shift in nephrology. Kidney Int 1996; 49: 1774-1777.
3. Remuzzi G, Perico N, Macia M, Ruggenenti P: The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int Suppl 2005; 99: S57-S65.
4. Carmines PK, Mitchell KD, Navar LG: Effects of calcium antagonists on renal hemodynamics and glomerular function. Kidney Int Suppl 1992; 36: S43-S48.
5. Hayashi K, Ozawa Y, Fujiwara K, Wakino S, Kumagai H, Saruta T: Role of actions of calcium antagonists on efferent arterioles - with special references to glomerular hypertension. Am J Nephrol 2003; 23: 229-244.
6. 2+ channels and drug development. J Pharmacol Sci 2005; 99: 214-220.
7. Richard S: Vascular effects of calcium channel antagonists: new evidence. Drugs 2005; 65 (Suppl 2): 1-10.
8. Sato A, Hayashi K, Saruta T: Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 2005; 18: 44-49.
9. Imagawa K, Okayama S, Takaoka M, et al: Inhibitory effect of efonidipine on aldosterone synthesis and secretion in human adrenocarcinoma (H295R) cells. J Cardiovasc Pharmacol 2006; 47: 133-138.
10. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157: 2413-2446.
11. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
12. Peterson JC, Adler S, Burkart JM, et al: Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995; 123: 754-762.
13. Remuzzi G, Chiurchiu C, Ruggenenti P: Proteinuria predicting outcome in renal disease: nondiabetic nephropathies (REIN). Kidney Int Suppl 2004; 92: S90-S96.
14. de Zeeuw D, Remuzzi G, Parving HH, et al: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004; 65: 2309-2320.
15. Hunsicker LG, Atkins RC, Lewis JB, et al: Impact of irbesartan, blood pressure control, and proteinuria on renal outcomes in the Irbesartan Diabetic Nephropathy Trial. Kidney Int Suppl 2004; 92: S99-S101.
16. Abbate M, Benigni A, Bertani T, Remuzzi G: Nephrotoxicity of increased glomerular protein traffic. Nephrol Dial Transplant 1999; 14: 304-312.
17. Abbate M, Zoja C, Morigi M, et al: Transforming growth factor-betal is up-regulated by podocytes in response to excess intraglomerular passage of proteins: a central pathway in progressive glomerulosclerosis. Am J Pathol 2002; 161: 2179-2193.
18. Kannel WB, Stampfer MJ, Castelli WP, Verter J: The prognostic significance of proteinuria: the Framingham study. Am Heart J 1984; 108: 1347-1352.
19. Culleton BF, Larson MG, Parfrey PS, Kannel WB, Levy D: Proteinuria as a risk factor for cardiovascular disease and mortality in older people: a prospective study. Am J Med 2000; 109: 1-8.
20. Dykeman-Sharpe J: Proteinuria, a modifiable risk factor: angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers; (ARBs). CANNT J 2003; 13: 34-38.
21. Raij L: Recommendations for the management of special populations: renal disease in diabetes. Am J Hypertens 2003; 16: 46S-49S.
22. Ruggenenti P: Angiotensin-converting enzyme inhibition and angiotensin II antagonism in nondiabetic chronic nephropathies. Semin Nephrol 2004; 24: 158-167.
23. 2+ channels with efonidipine decreased plasma aldosterone concentration in healthy volunteers. Hypertens Res 2006; 29: 493-497.
24. Oshima T, Ozono R, Yano Y, et al: Beneficial effect of T-type calcium channel blockers on endothelial function in patients with essential hypertension. Hypertens Res 2005; 28: 889-894.
25. Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-126.
26. Landmesser U, Hornig B, Drexler H: Endothelial function: a critical determinant in atherosclerosis? Circulation 2004; 109 (Suppl. 1): II27-II33.
27. Madamanchi NR, Vendrov A, Runge MS: Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol 2005; 25: 29-38.
28. Brewster UC, Setaro JF, Perazella MA: The renin-angiotensin-aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states. Am J Med Sci 2003; 326: 15-24.
29. Struthers AD, MacDonald TM: Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc Res 2004; 61: 663-670.
30. Tonelli M, Wiebe N, Culleton B, et al: Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006; 17: 2034-2047.